two
seri
new
aromat
thiosemicarbazon
deriv
synthes
condens
n
hydrazin
carbothioamid
n
hydrazin
carbothioamid
ii
appropri
aromat
aldehyd
order
investig
antivir
cytostat
potenc
chemic
structur
compound
fulli
character
element
analysi
spectroscop
techniqu
result
bioassay
indic
compound
id
ie
iif
prove
inhibitori
influenza
viru
ec
mgml
strain
mgml
strain
compound
ig
iig
cytostat
compound
inhibit
hela
cell
prolifer
ic
mgml
ig
mgml
iig
especi
compound
ig
show
highest
cytostat
activ
ic
mgml
hela
cem
cell
line
respect
inhibit
rang
within
order
magnitud
cisplatin
furthermor
molecular
model
carri
examin
cytostat
activ
determin
best
pharmacophor
model
guid
design
develop
potenti
prodrug
futur
studi
thiosemicarbazon
import
class
synthet
product
potenti
biolog
activ
compound
domagk
et
al
first
report
thiosemicarbazon
pharmacophor
antituberculosi
activ
antivir
activ
benzaldehyd
thiosemicarbazon
deriv
vaccina
viru
mice
found
hamr
et
al
antivir
activ
isatinbthiosemicarbazon
ibt
nmethylisatinbthiosemicarbazon
commerci
known
methisazon
marboran
wide
investig
orthopoxvirus
discoveri
thiosemicarbazon
draw
consider
interest
due
applic
pharmaceut
chemistri
prove
chemotherapeut
agent
potenti
use
inhibit
cancer
cell
exampl
thiosemicarbazon
commerci
known
triapin
inhibit
biosynthesi
dna
murin
leukemia
cell
block
activ
ribonucleotid
reductas
recent
year
commonli
accept
agent
contain
one
pharmacophor
superior
efficaci
compar
singlepharmacophor
drug
pharmacophor
hybrid
method
ration
drug
design
singl
molecul
contain
differ
mode
action
benefici
treatment
diseas
import
pharmacophor
bisalkyl
nitrogen
mustard
chlormethin
melphalan
chlorambucil
mani
anticanc
activ
hematolog
tumor
myeloma
ovarian
cancer
solid
tumor
alkyl
agent
electrophil
entiti
interact
nucleophil
moieti
dna
result
coval
transfer
alkyl
group
anoth
pharmacophor
parasubstitut
aryl
nitril
bioisoster
keton
group
varieti
anticanc
activ
eg
hormonallyrespons
breast
cancer
letrozol
breast
cancer
neratinib
prostat
cancer
bicalutamid
pancreat
cancer
nonsmal
cell
lung
cancer
head
neck
cancer
phase
chronic
myelogen
leukemia
bosutinib
phase
iii
previous
report
vitro
cytostat
broadspectrum
antivir
activ
thiosemicarbazon
deriv
platinum
ii
palladium
ii
complex
encourag
result
aim
develop
effect
anticanc
agent
design
two
seri
thiosemicarbazon
pharmacophor
hybrid
method
use
two
differ
pharmacophor
view
prospect
cytostat
antivir
activ
fig
order
gain
detail
inform
issu
develop
effect
anticanc
agent
futur
studi
perform
virtual
screen
aforement
compound
use
discoveri
studio
softwar
intermedi
n
hydrazinecarbothioamid
n
hydrazinecarbothioamid
ii
prepar
isothiocyan
isothiocyan
reaction
hydrazin
monohydr
respect
n
hydrazinecarbothioamid
report
previous
n
hydrazinecarbothioamid
ii
commerci
avail
novel
thiosemicarbazon
ia
ig
iia
iig
well
known
analog
ib
synthes
high
yield
correspond
treatment
thiosemicarbazid
methanol
accord
gener
procedur
previous
describ
method
synthet
rout
target
compound
ia
ig
iia
iig
shown
scheme
chemic
structur
new
compound
throughli
elud
element
analysi
spectral
data
uvvi
ir
h
nmr
c
nmr
esim
assign
select
diagnost
ir
band
provid
signific
indic
format
thiosemicarbazon
deriv
thiosemicarbazon
deriv
iag
iiag
exhibit
two
intens
band
region
cm
cm
due
n
nh
stretch
strong
band
cm
present
due
n
cs
stretch
suggest
thiosemicarbazon
solid
phase
remain
thion
form
addit
characterist
azomethin
stretch
vibrat
n
cn
cm
observ
also
confirm
format
thiosemicarbazon
result
h
nmr
integr
signal
multipl
line
propos
structur
spectral
data
h
nmr
spectra
ia
ig
iia
iig
show
singlet
peak
attribut
nnh
proton
arang
ppm
well
singlet
peak
attribut
phnh
proton
rang
ppm
signal
azomethin
proton
hcn
appear
singlet
ppm
aromat
proton
observ
expect
chemic
shift
ppm
coupl
constant
nmr
spectra
thiosemicarbazon
deriv
c
nmr
spectra
thiosemicarbazon
exhibit
two
import
signal
ppm
assign
thioamid
cs
imin
cn
carbon
atom
respect
signal
ppm
spectra
assum
due
aromat
carbon
ms
spectra
thiosemicarbazon
line
propos
structur
progress
reaction
monitor
thin
layer
chromatographi
tlc
tlc
perform
silica
gel
plate
merck
silica
gel
f
mm
visual
exposur
iodin
vapor
uv
light
use
etoachexan
vv
solvent
system
melt
point
determin
ezmelt
autom
melt
point
apparatu
uncorrect
ir
spectra
record
perkin
elmer
ftir
spectromet
univers
atr
sampl
accessori
h
nmr
c
nmr
spectra
obtain
room
temperatur
bruker
nmr
spectromet
dmsod
use
tm
intern
standard
mass
spectra
obtain
use
lcm
agil
msd
seri
spectromet
electrospray
mode
element
chn
analys
perform
use
variomicro
element
analyz
gener
procedur
hot
solut
thiosemicarbazid
mmol
methanol
ml
ad
dropwis
solut
appropri
aldehyd
mmol
methanol
ml
continu
stir
addit
catalyt
amount
glacial
acet
acid
reaction
mixtur
reflux
h
progress
reaction
monitor
tlc
reaction
mixtur
cool
precipit
filter
crude
product
wash
cold
diethyleth
ethanol
recrystal
appropri
solvent
tabl
orang
solid
aceton
yield
g
mp
antivir
assay
base
inhibit
virusinduc
cytopath
confluent
cell
cultur
cytostat
assay
inhibit
tumor
cell
prolifer
exponenti
grow
tumor
cell
cultur
accord
previous
describ
method
synthes
compound
evalu
follow
virus
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
g
cytomegaloviru
strain
david
varicella
zoster
viru
vzv
strain
oka
ys
vaccinia
viru
lederl
strain
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
viru
parainfluenza
viru
influenza
viru
subtyp
influenza
viru
b
sindbi
punta
toro
viru
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
vzv
human
embryon
lung
hel
fibroblast
african
green
monkey
cell
vero
human
epitheli
cervix
carcinoma
cell
hela
madindarbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
cmv
respect
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
effect
concentr
defin
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
inhibit
iii
b
rod
induc
cytopath
cem
cell
cultur
measur
microtit
plate
cem
cellsml
infect
ccid
hiv
per
millilit
contain
appropri
dilut
test
compound
day
incub
co
control
humidifi
atmospher
cem
giant
syncytium
cell
format
examin
microscop
character
ec
valu
effect
concentr
inhibit
hivinduc
giant
cell
format
cytostatictox
activ
assay
perform
microlit
plate
well
ad
tumor
cell
given
amount
test
compound
cell
allow
prolifer
h
murin
leukemia
cell
h
human
cd
tlymphocyt
cem
human
cervix
carcinoma
hela
cell
humidifi
co
control
atmospher
end
incub
period
cell
count
coulter
counter
ic
inhibitori
concentr
defin
concentr
compound
inhibit
cell
prolifer
cisplatin
purchas
sigma
use
refer
drug
compound
concentr
mgml
test
dilut
data
repres
mean
sd
standard
deviat
least
two
three
independ
experi
valu
significantli
differ
cisplatin
less
activ
except
ig
statist
differ
p
biolog
activ
depend
chemic
structur
substitu
also
three
dimension
configur
compound
ig
reason
appli
comput
method
ligandbas
pharmacophor
model
evalu
state
new
deriv
thiosemicarbazon
ia
ig
iia
iig
drawn
convert
basi
set
assign
minim
use
semiempir
method
aid
program
packag
conform
search
ligand
carri
use
best
algorithm
pharmacophor
gener
auto
pharmacophor
gener
protocol
discoveri
studio
use
base
bioactiv
conform
studi
use
compound
ig
bioactiv
conform
ic
valu
mgml
pharmacophor
model
gener
base
main
featur
compound
ig
featur
hbacceptor
hbdonor
hydrophob
ring
aromat
pharmacophor
model
besid
genet
function
approxim
gfa
model
select
pharmacophor
use
best
model
determin
help
cluster
pharmacophor
subprotocol
model
contain
six
featur
repres
two
hydrophob
cyan
two
ring
aromat
orang
one
hydrogen
bond
donor
pink
one
hydrogen
acceptor
green
newli
synthes
compound
evalu
antivir
cytostat
cytotox
properti
none
compound
effect
inhibit
dna
viru
replic
ie
vv
except
ii
show
slight
activ
vaccinia
viru
replic
hel
cell
cultur
ec
mgml
compound
ib
ic
iic
bear
electrondon
group
oh
och
felin
herp
viru
ec
mgml
compound
also
significantli
inhibitori
wide
varieti
rna
virus
includ
vesicular
stomat
viru
vsv
respiratori
syncyti
viru
coxsacki
viru
hela
cell
cultur
subtox
concentr
tabl
howev
vero
cell
cultur
compound
ig
consist
show
antivir
activ
mgml
ec
coxsacki
viru
inhibitori
activ
observ
parainfluenza
sindbi
viru
punta
toro
viru
tabl
fact
activ
ig
coxsacki
viru
observ
one
cell
line
monkey
kidney
vero
anoth
cell
line
human
cervix
carcinoma
hela
led
us
conclud
compound
consid
consist
new
antivir
lead
agent
margin
activ
observ
ib
ic
iic
felin
herp
viru
ec
mgml
ib
ic
iia
felin
corona
fipv
viru
ec
mgml
crfk
cell
cultur
tabl
wherea
activ
found
mdck
cell
cultur
influenza
b
viru
compound
id
ie
iif
electronwithdraw
group
cf
f
prove
inhibitori
influenza
viru
ec
mgml
strain
mgml
strain
compound
less
effect
clinic
use
drug
oseltamivir
neither
cytotox
mcc
cytostat
cc
mgml
mdck
cell
tabl
thu
certain
degre
select
present
compound
influenza
viru
cell
cultur
consid
optim
potenti
antiinfluenza
viru
lead
compound
synthes
compound
also
evalu
cytostat
activ
murin
leukemia
human
cd
tlymphocyt
cem
cervix
carcinoma
hela
cell
tabl
compound
iia
iig
seri
show
pronounc
cytostat
activ
ic
mgml
howev
iib
moder
cytostat
ic
mgml
wherea
iig
seem
poorli
inhibitori
cem
cell
prolifer
pronounc
antiprolif
activ
hela
cell
ic
mgml
unusu
select
tumor
cell
line
investig
fact
seri
compound
often
somewhat
cytostat
correspond
ii
seri
compound
may
coincid
ig
ic
mgml
hela
cell
also
cytostat
among
seri
also
show
pronounc
antiprolif
potenc
hela
cell
structur
activ
relationship
sar
studi
perform
determin
substitu
benzen
ring
affect
cytostat
activ
compound
ia
iia
without
substitu
group
benzen
ring
show
cytostat
activ
examin
effect
introduc
variou
substitu
group
benzen
ring
compound
ia
iia
oh
och
cf
f
n
ch
ch
cl
group
para
posit
benzen
ring
compound
ia
iia
use
form
compound
punta
toro
viru
ia
ib
ic
id
ie
ig
ii
iia
iib
iic
iid
iie
iif
iig
dextran
sulfat
molecular
weight
dhpa
adenin
ib
ig
iib
iig
especi
ig
bi
amino
moieti
ic
valu
mgml
lowest
effect
among
compound
compar
cisplatin
refer
compound
twotail
unpair
ttest
graphpad
prism
reveal
signific
differ
cytostat
inhibit
valu
ig
cisplatin
obtain
three
tumor
cell
line
p
result
show
compound
ia
ig
contain
electronwithdraw
group
cn
locat
para
posit
benzen
ring
increas
cytostat
activ
accord
electrondon
group
sch
posit
structur
like
compound
synthesi
biolog
evalu
ligand
iia
iig
furthermor
introduct
electrondon
group
oh
och
para
posit
benzen
ring
weaken
cytostat
effect
situat
electronwithdraw
group
f
cf
also
observ
compound
iib
exhibit
moder
activ
tumor
cell
type
besid
compound
display
better
cytostat
activ
analog
compound
iig
electrondon
group
sch
para
posit
result
indic
introduct
bulki
alkyl
group
bi
amino
cyano
group
reinforc
cytostat
activ
pharmacophor
model
fig
hypothet
superimpos
compound
ig
fit
valu
iig
fit
valu
figur
summar
result
model
fit
obtain
compound
ig
iig
compound
superimpos
fit
best
model
addit
compar
result
model
experiment
data
show
compat
signific
trend
establish
hbacceptor
cn
sch
hydrophob
group
n
ch
ch
cl
respons
cytostat
activ
compound
ig
iig
accord
ligandbas
pharmacophor
model
especi
investig
compound
show
major
effect
studi
unfortun
compound
ia
iia
iif
show
activ
comparison
compound
ig
iig
propos
method
abl
provid
valuabl
inform
key
featur
interact
import
biolog
activ
compound
ig
thu
ligandbas
pharmacophor
model
increasingli
success
delin
compound
ig
display
better
cytostat
activ
compound
iig
